Pharmaceutical

Novelion Therapeutics (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017 and provided an overview of recent business activities. As quoted in the press release: Chief Operating Officer Jeff Hackman said, “We are …

Novelion Therapeutics (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017 and provided an overview of recent business activities.

As quoted in the press release:

Chief Operating Officer Jeff Hackman said, “We are focused on executing near-term plans that we believe will position our company for sustainable future growth. These priorities include cost control and expense management, reviewing our holding and capital structure with a view toward optimizing our assets for shareholders, advancing the metreleptin development program, and continuing to provide important therapies to our patients.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX19837.25-52.81
TSXV700.90-10.29
DOW31834.11-326.63
S&P 5003935.18-65.87
NASD11364.24-373.44
ASX7064.70+13.50

COMMODITIES

Commodities
Gold1842.28-11.82
Silver20.93-0.60
Copper4.05-0.16
Palladium1927.00-94.00
Platinum966.78-24.72
Oil104.10-1.61
Heating Oil3.67-0.08
Natural Gas7.47-0.17

DOWNLOAD FREE REPORTS

×